TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Interaction Details
01. General Information
Pair Name Bisdemethoxycucurmin, Icotinib
Phytochemical Name Bisdemethoxycucurmin (PubChem CID: 5315472 )
Anticancer drug Name Icotinib (PubChem CID: 22024915 )
Structure of
Phytochemical
2D-img
Download
2D MOL 3D MOL
Structure of
Anticancer Drug
2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 499
Pair Name Bisdemethoxycucurmin, Icotinib
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Biological Phenomena Induction-->Apoptosis and autophagy
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
Up-regulation Phosphorylation ATM hsa472
Up-regulation Expression BECN1 hsa8678
Down-regulation Expression BIRC5 hsa332
Up-regulation Cleavage CASP7 hsa840
Up-regulation Expression CDH1 hsa999
Up-regulation Phosphorylation CHEK1 hsa1111
Up-regulation Expression CYCS hsa54205
Up-regulation Expression DNAJB4 hsa11080
Down-regulation Phosphorylation EGFR hsa1956
Down-regulation Expression ERBB2 hsa2064
Up-regulation Expression GSK3B hsa2932
Up-regulation Expression H2AX hsa3014
Down-regulation Expression HDAC1 hsa3065
Down-regulation Expression HDAC2 hsa3066
Down-regulation Expression HK1 hsa3098
Up-regulation Expression JUND hsa3727
Down-regulation Expression MAP1LC3A hsa84557
Up-regulation Expression MAP1LC3B hsa81631
Down-regulation Phosphorylation MAPK8 hsa5599
Down-regulation Expression MET hsa4233
Down-regulation Expression MMP2 hsa4313
Down-regulation Expression MMP9 hsa4318
Up-regulation Cleavage PARP1 hsa142
Down-regulation Expression SQSTM1 hsa8878
Up-regulation Phosphorylation TRIM28 hsa10155
Up-regulation Expression VDAC1 hsa7416
Down-regulation Expression VDAC2 hsa7417
Down-regulation Expression VEGFA hsa7422
In Vitro Model NCI-H460 Lung large cell carcinoma Homo sapiens (Human) CVCL_0459
NCI-H1781 Minimally invasive lung adenocarcinoma Homo sapiens (Human) CVCL_1494
Result Our data indicate that BMDC has the potential to improve the treatment of primary EGFR-TKI resistant NISCLC that cannot be controlled with single-target agent, such as icotinib.
03. Reference
No. Title Href
1 Our data indicate that BMDC has the potential to improve the treatment of primary EGFR-TKI resistant NISCLC that cannot be controlled with single-target agent, such as icotinib. Click
It has been 48187 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP